It is our great pleasure to announce that Robert Kalb, MD from the University of Pennsylvania has been selected as the first Director of the Les Turner ALS Research and Patient Center at Northwestern Medicine, Chief of Division of Neuromuscular …
Radicava is Now Available for Treatment in U.S
Mitsubishi Tanabe Pharma America, Inc., today announced RADICAVA ™ (edaravone), an intravenous therapy indicated for all adult patients diagnosed with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is now available for treatment in the United States. RADICAVA, …
ALS Ice Bucket Challenge: Three Years Later
In 2014, the ALS Ice Bucket Challenge swept the globe, forever changing the face of ALS. Millions of dollars were raised and awareness reached an all time high. Three years later, major advances in ALS research and patient care have …
Join the ALS Registry
In the next year alone, about 5,000 people in the U.S. may be diagnosed with #ALS. The National #ALSRegistry is connecting persons living with ALS with researchers who want to find the causes of the disease, help those diagnosed, and …
Investing in our Future: Funding ALS Research
Each year, the Les Turner ALS Foundation provides a grant to the Les Turner ALS Research and Patient Center at Northwestern Medicine. This grant provides support to the Lois Insolia ALS Clinic as well as researchers looking for answers on …
Radicava FAQs
Les Turner ALS Research and Patient Center at Northwestern Medicine On May 5, the FDA approved a new drug to treat ALS. Radicava™ (also known as Edaravone) is the first approved ALS-specific drug since Riluzole, which was approved 22 years …
New Gene Identified in ALS
(May 15, 2017)- For the first time, a variant in UBQLN4 gene has been associated with Lou Gehrig’s disease or amyotrophic lateral sclerosis (ALS) – a progressive disease resulting in the loss of nerve cells that control muscle movement, which …
MT Pharma America Announces FDA Approval of RADICAVA™ (Edaravone)
Just today, we learned the FDA has approved the first new drug for ALS in 22 years! The new drug is called Radicava and has been demonstrated to slow decline of physical function by 33 percent. The timing of this …
The National ALS Biorepository Launched – “Learn How to Participate”
One of the questions that people living with ALS often ask is – what can I do to help ALS Research? ALS patients can do that, with a personal contribution to the National ALS Registry (Registry) – in the newly …
April Special Events eNewsletter
Want to stay updated about the latest Foundation events? Subscribe to our mailing list to receive monthly eNewsletters. Read our April Edition to learn more.
